Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Liver Cirrhosis

  Free Subscription


Articles published in Gastroenterology

Retrieve available abstracts of 53 articles:
HTML format



Single Articles


    October 2025
  1. ORMAN ES, Fortune BE, John BV, Asrani SK, et al
    AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review.
    Gastroenterology. 2025 Oct 20:S0016-5085(25)05959.
    PubMed     Abstract available


    September 2025
  2. ROHM TV, Dos Reis FCG, Cunha E Rocha K, Isaac R, et al
    Adipose Tissue Macrophages in Metabolic Dysfunction-Associated Steatohepatitis Secrete Extracellular Vesicles That Activate Liver Fibrosis in Obese Male Mice.
    Gastroenterology. 2025;169:691-704.
    PubMed     Abstract available


    August 2025
  3. LOU TW, Ren TY, Fan JG
    An Unusual Cause of Hypolipidemia With Cirrhosis in a Father-Son Pair.
    Gastroenterology. 2025 Aug 21:S0016-5085(25)05901.
    PubMed    


  4. LIU WY, Huang S, Ji H, Kim SU, et al
    From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective.
    Gastroenterology. 2025;169:326-336.
    PubMed     Abstract available


    July 2025
  5. SILVEY S, Kamath PS, George J, Choudhury A, et al
    Enhancement of Inpatient Mortality Prognostication with Machine Learning in a Prospective Global Cohort of Patients with Cirrhosis with External Validation.
    Gastroenterology. 2025 Jul 18:S0016-5085(25)05770.
    PubMed     Abstract available


    June 2025
  6. BAJAJ JS, Shawcross DL, Choudhury A, Karvellas CJ, et al
    Defining Organ Failures in Patients with Cirrhosis: Consensus Statements.
    Gastroenterology. 2025 Jun 9:S0016-5085(25)00844.
    PubMed    


  7. MCGETTIGAN B, Hernandez-Tejero M, Malhi H, Shah V, et al
    Immune Dysfunction and Infection Risk in Advanced Liver Disease.
    Gastroenterology. 2025;168:1085-1100.
    PubMed     Abstract available


    May 2025
  8. JUANOLA A, Ma AT, Cullaro G, Alexander MP, et al
    DEVELOPMENT OF ACUTE KIDNEY INJURY IN A PATIENT WITH ALCOHOL-RELATED CIRRHOSIS: THE IMPORTANCE OF DIAGNOSING THE CAUSE OF AKI.
    Gastroenterology. 2025 May 19:S0016-5085(25)00764.
    PubMed    


    April 2025
  9. LENS S
    Simvastatin and Rifaximin for Decompensated Cirrhosis: A Hope Unfulfilled.
    Gastroenterology. 2025 Apr 23:S0016-5085(25)00638.
    PubMed    


  10. GUPTA V, Sehrawat TS, Pinzani M, Strazzabosco M, et al
    Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.
    Gastroenterology. 2025;168:675-690.
    PubMed     Abstract available


    March 2025
  11. SILVEY S, Patel N, Khoruts A, Bajaj JS, et al
    Rifaximin does not increase the rate of 30-day mortality in patients with cirrhosis and daptomycin in two National US-based cohorts.
    Gastroenterology. 2025 Mar 21:S0016-5085(25)00535.
    PubMed    


  12. KISSELEVA T, Ganguly S, Murad R, Wang A, et al
    Regulation of Hepatic Stellate Cell Phenotypes in MASH.
    Gastroenterology. 2025 Mar 20:S0016-5085(25)00528.
    PubMed     Abstract available


    February 2025
  13. FROMME M, Payance A, Mandorfer M, Thorhauge KH, et al
    Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi *ZZ Genotype).
    Gastroenterology. 2025;168:367-381.
    PubMed     Abstract available


    January 2025
  14. KUMAR N, Chaudhary A
    Comments on "Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program".
    Gastroenterology. 2025 Jan 30:S0016-5085(25)00326.
    PubMed    


  15. RHEE H, Kim MJ, Kim DY, An C, et al
    Non-contrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance: A randomized, single-center trial.
    Gastroenterology. 2025 Jan 22:S0016-5085(25)00049.
    PubMed     Abstract available


    December 2024
  16. DAVIS JPE, Lim JK, Francis FF, Ahn J, et al
    AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review.
    Gastroenterology. 2024 Dec 20:S0016-5085(24)05664.
    PubMed     Abstract available


    November 2024
  17. FUJIWARA N, Lopez C, Marsh TL, Raman I, et al
    Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis.
    Gastroenterology. 2024 Nov 7:S0016-5085(24)05660.
    PubMed     Abstract available


  18. DORNER H, Stolzer I, Mattner J, Kaminski S, et al
    Gut Pathobiont-Derived Outer Membrane Vesicles Drive Liver Inflammation and Fibrosis in Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease.
    Gastroenterology. 2024;167:1183-1197.
    PubMed     Abstract available


    October 2024
  19. CLARK VC, Strange C, Strnad P, Sanchez AJ, et al
    Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA).
    Gastroenterology. 2024;167:1008-1018.
    PubMed     Abstract available


    September 2024
  20. MAK LY, Yuen MF
    Surveillance for hepatocellular carcinoma in cirrhosis: End of monopoly for serum alpha fetoprotein.
    Gastroenterology. 2024 Sep 28:S0016-5085(24)05533.
    PubMed    


  21. MARSH TL, Parikh ND, Roberts LR, Schwartz ME, et al
    A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis.
    Gastroenterology. 2024 Sep 16:S0016-5085(24)05460.
    PubMed     Abstract available


    August 2024
  22. PREMKUMAR M, Dhiman RK, Duseja A, Mehtani R, et al
    Recompensation of Chronic Hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: Prospective Cohort study from an HCV elimination program.
    Gastroenterology. 2024 Aug 22:S0016-5085(24)05359.
    PubMed     Abstract available


    July 2024
  23. VAN KLEEF LA, Francque SM, Prieto-Ortiz JE, Sonneveld MJ, et al
    Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction.
    Gastroenterology. 2024;167:357-367.
    PubMed     Abstract available


    June 2024
  24. VENKATESWARAN N
    Seladelpar as an alternate second line agent for Primary Biliary Cirrhosis.
    Gastroenterology. 2024 Jun 20:S0016-5085(24)05064.
    PubMed    


  25. ZHU CP, Liu SQ, Wang KQ, Xiong HL, et al
    Targeting 5-Hydroxytryptamine receptor 1A in portal vein to decrease portal hypertension.
    Gastroenterology. 2024 Jun 19:S0016-5085(24)05062.
    PubMed     Abstract available


    May 2024
  26. HANSCOM M
    Magnetically guided capsule endoscopy comparable to EGD for detecting esophagogastric varices in patients with cirrhosis.
    Gastroenterology. 2024 May 28:S0016-5085(24)05001.
    PubMed    


  27. WANG R, Li B, Huang B, Li Y, et al
    Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis.
    Gastroenterology. 2024 May 27:S0016-5085(24)04936.
    PubMed     Abstract available


  28. HILSCHER MB, Wysokinski WE, Andrews JC, Simonetto DA, et al
    Portal Vein Thrombosis in the Setting of Cirrhosis: Evaluation and Management Strategies.
    Gastroenterology. 2024 May 25:S0016-5085(24)04951.
    PubMed    


    March 2024
  29. GAO F, Seto WK, Zheng MH
    Preventing Overdiagnosis of Nonalcoholic Fatty Liver Disease: Established Cutoff Values for Transient Elastography Are Needed.
    Gastroenterology. 2024;166:541-542.
    PubMed    


  30. AN T, Liu L, Li X
    Factors Associated With the Influence of Liver Fibrosis Should Be Fully Considered.
    Gastroenterology. 2024;166:540-541.
    PubMed    


    February 2024
  31. WONG RJ, Yang Z, Cheung R, Singal AK, et al
    Impact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among U.S. Veterans with Steatotic Liver Disease.
    Gastroenterology. 2024 Feb 28:S0016-5085(24)00238.
    PubMed     Abstract available


  32. LENS S
    In Search of the Best Second-Line Therapy for Primary Biliary Cholangitis.
    Gastroenterology. 2024 Feb 20:S0016-5085(24)00185.
    PubMed    


  33. TRIVEDI PJ, Hirschfield GM, Adams DH, Vierling JM, et al
    Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts.
    Gastroenterology. 2024 Feb 9:S0016-5085(24)00165.
    PubMed     Abstract available


    January 2024
  34. POSE E, Piano S, Juanola A, Gines P, et al
    HEPATORENAL SYNDROME IN CIRRHOSIS.
    Gastroenterology. 2024 Jan 19:S0016-5085(24)00054.
    PubMed     Abstract available


  35. LAURIDSEN MM, Gronkjaer LL, Khraibut S, Patel N, et al
    The multi-dimensional challenge of poor oral health in cirrhosis - disparities and solutions.
    Gastroenterology. 2024 Jan 13:S0016-5085(24)00043.
    PubMed    


    November 2023
  36. GARCIA-TSAO G, Abraldes JG, Rich NE, Wong VW, et al
    AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Gastroenterology. 2023 Nov 17:S0016-5085(23)05143.
    PubMed     Abstract available


    October 2023
  37. AMPUERO J, Berzigotti A
    Prognostication in Advanced Chronic Liver Disease Using Liver Stiffness Measurement: Repetita Iuvant.
    Gastroenterology. 2023;165:829-831.
    PubMed    


  38. SEMMLER G, Yang Z, Fritz L, Kock F, et al
    Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.
    Gastroenterology. 2023;165:1041-1052.
    PubMed     Abstract available


  39. MAN S, Deng Y, Ma Y, Fu J, et al
    Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China.
    Gastroenterology. 2023;165:1025-1040.
    PubMed     Abstract available


  40. WATTACHERIL JJ, Abdelmalek MF, Lim JK, Sanyal AJ, et al
    AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Gastroenterology. 2023;165:1080-1088.
    PubMed     Abstract available


    September 2023
  41. XIE L, Guo H
    Question on the use of BMI >/= 25 kg/m(2) to define obesity to analyze the incidence and risk factors of hepatic steatosis and hepatic fibrosis in the Chinese population.
    Gastroenterology. 2023 Sep 8:S0016-5085(23)04983.
    PubMed    


  42. WANG Y, Huang Y, Chase RC, Li T, et al
    Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019.
    Gastroenterology. 2023;165:773-783.
    PubMed     Abstract available


  43. INTAGLIATA NM, Rahimi RS, Higuera-de-la-Tijera F, Simonetto DA, et al
    Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study.
    Gastroenterology. 2023;165:717-732.
    PubMed     Abstract available


  44. ZUO T, Xie Q, Liu J, Yang J, et al
    Macrophage-Derived Cathepsin S Remodels the Extracellular Matrix to Promote Liver Fibrogenesis.
    Gastroenterology. 2023;165:746-761.
    PubMed     Abstract available


    August 2023
  45. HUANG DQ, Wilson LA, Behling C, Kleiner DE, et al
    Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.
    Gastroenterology. 2023;165:463-472.
    PubMed     Abstract available


  46. PENG Z, Li S, Pi R
    A Giant Cystic Liver Mass in an Elderly Man.
    Gastroenterology. 2023;165:e5-e7.
    PubMed    


    July 2023
  47. REDDY KR, McLerran D, Marsh T, Parikh N, et al
    Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: the Multi-center Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.
    Gastroenterology. 2023 Jul 8:S0016-5085(23)04765.
    PubMed     Abstract available


    June 2023
  48. THIELE M, Suvitaival T, Trost K, Kim M, et al
    Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis.
    Gastroenterology. 2023;164:1248-1260.
    PubMed     Abstract available


    May 2023
  49. FARIAS AQ, Vilalta AC, Zitelli PM, Pereira G, et al
    Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.
    Gastroenterology. 2023 May 30:S0016-5085(23)00806.
    PubMed     Abstract available


    April 2023
  50. HAN H, Ge X, Babu Komakula SS, Desert R, et al
    MACROPHAGE-DERIVED OSTEOPONTIN (SPP1) PROTECTS FROM NON-ALCOHOLIC STEATOHEPATITIS.
    Gastroenterology. 2023 Apr 5:S0016-5085(23)00581.
    PubMed     Abstract available


    March 2023
  51. LIU R, Dai Z, Zhu C
    A Rare Cause of Liver Fibrosis in an Adolescent Woman.
    Gastroenterology. 2023;164:340-343.
    PubMed    


    February 2023
  52. TOH MR, Wong Yi Ting E, Wong Hei S, Ng Wei Tian A, et al
    Global epidemiology and genetics of hepatocellular carcinoma.
    Gastroenterology. 2023 Feb 2:S0016-5085(23)00105.
    PubMed     Abstract available


    November 2022
  53. WANG Z, Tai Y, Wu H
    A rare cause of abdominal pain after transjugular intrahepatic portosystemic shunt.
    Gastroenterology. 2022 Nov 10. pii: S0016-5085(22)01258.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.